Skip to content
OpenCapital
Get started

Candel Therapeutics, Inc. CADL Q2 2025 earnings

Reported August 14, 2025 · Before market open

EPS-$0.09Beat by $0.08
EPS estimate-$0.17

Next report

Aug 13, 2026 (In 2 weeks)
EPS estimate-$0.22

Financials

Q2 2025

Income statement

See full
Operating income-$11.2M-30.4%
Net income-$4.8M+78.4%
EPS (diluted)-$0.09+87.8%

Balance sheet

See full
Cash & equivalents$100.7M+369%
Total debt$8.3M-29.6%
Total equity$90.2M+1,005%
Total assets$106.0M+300%

Cash flow

See full
Operating cash flow-$8.9M-43.4%
CapEx$31.0K+417%
Free cash flow-$8.9M-43.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$243M+34.2%
Enterprise value$150.65M-12.1%

Returns & leverage

See full
Debt / equity0.1×—
Current ratio7×+5.4×

Versus estimates

Diluted EPS

Q1 2026-$0.14Beat by $0.08Q4 2025-$0.54Miss by $0.30Q3 2025-$0.21Miss by $0.04
Q2 2025-$0.09Beat by $0.08
Q1 2025$0.13Beat by $0.37Q4 2024-$0.40Miss by $0.17

Ask the moment Candel Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Candel Therapeutics, Inc. report Q2 2025 earnings?
Candel Therapeutics, Inc. (CADL) reported Q2 2025 earnings on August 14, 2025 before market open.
What were Candel Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Candel Therapeutics, Inc. reported eps of $-0.09 for Q2 2025.
Did Candel Therapeutics, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.17 by $0.08.
How did Candel Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 87.8% from $-0.74.
Where can I find Candel Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-108450) directly on SEC EDGAR. The filing index links above go to sec.gov.